Welcome to our dedicated page for NAYA Biosciences news (Ticker: NAYA), a resource for investors and traders seeking the latest updates and insights on NAYA Biosciences stock.
NAYA Biosciences (NAYA) delivers innovative solutions through its dual focus on fertility care and clinical-stage oncology/autoimmune therapies. This page provides official updates across all business segments, offering stakeholders a centralized resource for tracking corporate developments.
Access timely press releases covering financial results, regulatory milestones, and strategic partnerships. Our curated news collection includes updates on clinical trials leveraging NAYA's proprietary FLEX antibody platform, operational expansions in women's health services, and technological advancements in bifunctional antibody development.
Key content categories include quarterly earnings reports, FDA clearance announcements, research collaborations, and product launch updates. The hub and spoke operational model - combining stable fertility clinic revenues with high-potential therapeutic R&D - remains a recurring theme across developments.
Bookmark this page for direct access to primary source materials from NAYA Biosciences. Check regularly for updates on pipeline progress, including novel treatments for solid tumors and expanded access to cost-effective fertility solutions through INVOcell technology.
INVO Fertility (Nasdaq: NAYA) announced it will begin trading under the new symbol 'IVF' on April 28, 2025, following its strategic decision to separate its fertility and oncology businesses. The company, formerly known as NAYA Biosciences, will maintain its current CUSIP number.
CEO Steve Shum stated that the new ticker symbol reflects their focus on the fertility care market, particularly their strategy of building, acquiring, and operating fertility clinics in the United States. The company aims to expand access to innovative reproductive services and technologies, aligning with the recent U.S. Presidential executive order to reduce IVF costs and increase accessibility to fertility services.
NAYA Biosciences has announced a strategic separation of its fertility and oncology businesses, with the public company being renamed to INVO Fertility, Inc. The company's Nasdaq ticker will change from NAYA to IVF. The restructuring involves:
1. The public company (INVO Fertility) will focus on:
- Operating and expanding fertility clinics
- Distributing FDA-cleared INVOcell device
- Managing existing revenue-generating centers in Wisconsin, Alabama, and Georgia
2. The oncology division will become a private entity named NAYA Therapeutics, focusing on bifunctional antibodies development. INVO Fertility will retain a minority stake in NAYA Therapeutics to benefit from potential value appreciation.
The separation, effective April 14, 2025, aims to maximize shareholder value and enable focused operations for both entities. The transaction remains subject to definitive documents and necessary approvals. The company has filed an extension for its 2024 Annual Report.
NAYA Biosciences (NASDAQ: NAYA) has announced a 1-for-12 reverse stock split effective March 18, 2025, at 12:01 a.m. Eastern Time. The company's stock will continue trading under the symbol 'NAYA' on the Nasdaq Capital Market with a new CUSIP number 44984F609.
Under this reverse split, every 12 shares of common stock will be consolidated into 1 share, with fractional shares rounded up. Post-split, NAYA will have approximately 666,057 shares of common stock outstanding, and its authorized shares will be adjusted to 4,166,666.
The primary objective of this reverse split is to meet Nasdaq's minimum bid price requirement of $1.00 per share for continued listing, though compliance is not guaranteed. NAYA Biosciences focuses on breakthrough treatments in oncology, autoimmune diseases, women's health, and provides IVF and IVC fertility treatments.
NAYA Biosciences (NASDAQ: NAYA) has expressed support for a recent U.S. presidential executive order aimed at improving access to fertility treatments. The order directs the Domestic Policy Council to develop policy recommendations within 90 days to protect IVF access and reduce out-of-pocket expenses for families dealing with infertility.
As a provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture (IVC) fertility treatments, NAYA believes this initiative could positively impact its operations. The company highlighted that its FDA-cleared INVOcell device and IVC treatment process are "uniquely positioned to offer an efficient, effective, and more affordable treatment solution" aligned with the administration's cost-reduction goals.
NAYA operates fertility centers in Wisconsin, Alabama, and Georgia. CEO Steve Shum emphasized that "no one should have to choose between financial stability and starting a family" and committed to supporting efforts making fertility treatments more accessible and affordable.
NAYA Biosciences (NASDAQ: NAYA) has nominated five new board members with extensive biotechnology industry experience, to be approved at the shareholder meeting on March 10th, 2025. The nominations reflect the company's enhanced focus on oncology and autoimmune diseases.
The nominees include: Laurent Audoly, PhD, cofounder/CEO of PriveBio and former founding president/CEO of Kymera Therapeutics; Melissa Fensterstock, MPhil, MBA, advisor at Material Impact Fund; Prakash Raman, PhD, CEO of InduPro and former Novartis executive; Daniel Teper, PharmD, MBA, Founder & President of NAYA Biosciences; and Alexandra Urman, MPH, CEO of Aomics and healthcare innovation expert.
NAYA Biosciences (NASDAQ: NAYA) has announced the pricing of a $9.5 million public offering consisting of 13,615,171 units at $0.70 per unit. Each unit includes one share of common stock (or pre-funded warrant) and one warrant to purchase one share of common stock at an exercise price of $0.70, exercisable immediately and expiring in five years.
The offering, led by Maxim Group with Brookline Capital Markets as co-placement agent, is expected to close around January 14, 2025. The net proceeds will be used to fund the Wisconsin Fertility Institute purchase, redeem 4,000 shares of Series C-2 preferred stock ($4,000,000 stated value), settle outstanding debt obligations, and support clinical trials, product development, marketing, management team strengthening, working capital, and potential acquisitions.
NAYA Biosciences (NASDAQ: NAYA) announced the expansion of its bifunctional antibody pipeline with NY-500, a novel PD-1 x VEGF tetravalent bifunctional antibody for treating hepatocellular carcinoma (HCC) and other solid tumors. The company is developing NY-500 using its proprietary FLEX antibody platform and optimizing it through an AI partnership with MabSilico.
Recent clinical data with ivonescimab, a similar PD-1 x VEGF antibody, has demonstrated superiority over Keytruda® in non-small-cell lung cancer treatment. NAYA aims to initiate clinical trials for NY-500 in early 2026.
Additionally, NAYA is developing NY-303, a GPC3-targeting bifunctional antibody, currently in phase 1/2 clinical trials for HCC patients not responding to PD-1 +/- VEGF therapy. Recent data presented at SITC showed NY-303's ability to reverse resistance to PD-1 checkpoint blockage. Phase 1/2a clinical trials for NY-303 are expected to begin in 2025.
NAYA Biosciences (NASDAQ: NAYA) announced two presentations at the 2024 SITC Annual Meeting in Houston, focusing on their GPC3-targeting NK engager bispecific antibody NY-303. The first presentation demonstrates NY-303's ability to reverse resistance to PD-1 checkpoint blockade, converting 'cold' tumors to 'hot' ones, making them susceptible to immunotherapy. The second presentation showcases a Graph AI model analyzing GPC3 gene expression and NK cell tumor infiltration's influence on hepatocellular carcinoma survival rates. These insights support the planned Phase I/IIa clinical trials in H1 2025.
INVO Bioscience has announced a corporate name change to NAYA Biosciences Inc. and will begin trading under the new symbol 'NAYA' on October 22, 2024. This change follows the recent merger with NAYA Biosciences, completed on October 14th. The newly combined company will maintain its revenue-generating fertility business while expanding into oncology and autoimmune diseases.
CEO Steve Shum stated that the name change and new trading symbol better reflect their expanded corporate strategy. The company aims to combine scalable, profitable revenues from the fertility business with the potential of innovative therapeutics. Their hub-and-spoke model is designed to share resources and talent to accelerate the development of lean, agile subsidiaries.
